Research

Our recent publications are highlighted here, including pivotal research such as the efficacy trials of Truvada and Descovy as oral pre-exposure prophylaxis (PrEP) for HIV, and Apretude as long-acting PrEP for HIV.

Biomedical HIV Prevention Intervention Trials

The 3T Study: Transgender Youth and PrEP: PK, Safety, Uptake & Adherence

  • Yager J, Brooks KM, Brothers J, Mulligan K, Landovitz RJ, Reirden D, Malhotra M, Glenny C, Harding P, Powell T, Anderson PL, Hosek S. Gender-Affirming Hormone Pharmacokinetics Among Adolescent and Young Adult Transgender Persons Receiving Daily Emtricitabine/Tenofovir Disoproxil Fumarate. AIDS Res Hum Retroviruses. 2022 Aug 9. doi: 10.1089/AID.2022.0044. Epub ahead of print. PMID: 35815468.

  • Yager J, Brooks KM, Brothers J, Mulligan K, Landovitz R, Reirden D, Glenny C, Malhotra M, Anderson PL, Hosek S. Pharmacokinetics of emtricitabine/tenofovir disoproxil fumarate among transgender adolescents and young adults without HIV receiving gender affirming hormones. AIDS Res Hum Retroviruses. 2022 Aug 9. doi: 10.1089/AID.2022.0043. Epub ahead of print. PMID: 35943868.

HPTN 083: Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC), For Pre-Exposure Prophylaxis in HIV-Uninfected Cisgender Men and Transgender Women Who Have Sex With Men

  • Landovitz RJ, Donnell D, Clement ME, Hanscom B, Cottle L, Coelho L, Cabello R, Chariyalertsak S, Dunne EF, Frank I, Gallardo-Cartagena JA, Gaur AH, Gonzales P, Tran HV, Hinojosa JC, Kallas EG, Kelley CF, Losso MH, Madruga JV, Middelkoop K, Phanuphak N, Santos B, Sued O, Valencia Huamaní J, Overton ET, Swaminathan S, Del Rio C, Gulick RM, Richardson P, Sullivan P, Piwowar-Manning E, Marzinke M, Hendrix C, Li M, Wang Z, Marrazzo J, Daar E, Asmelash A, Brown TT, Anderson P, Eshleman SH, Bryan M, Blanchette C, Lucas J, Psaros C, Safren S, Sugarman J, Scott H, Eron JJ, Fields SD, Sista ND, Gomez-Feliciano K, Jennings A, Kofron RM, Holtz TH, Shin K, Rooney JF, Smith KY, Spreen W, Margolis D, Rinehart A, Adeyeye A, Cohen MS, McCauley M, Grinsztejn B; HPTN 083 Study Team. Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women. N Engl J Med. 2021 Aug 12;385(7):595-608. doi: 10.1056/NEJMoa2101016. PMID: 34379922; PMCID: PMC8448593.

DISCOVER: Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection

  • Ogbuagu O, Ruane PJ, Podzamczer D, Salazar LC, Henry K, Asmuth DM, Wohl D, Gilson R, Shao Y, Ebrahimi R, Cox S, Kintu A, Carter C, Das M, Baeten JM, Brainard DM, Whitlock G, Brunetta JM, Kronborg G, Spinner CD; DISCOVER study team. Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet HIV. 2021 Jul;8(7):e397-e407. doi: 10.1016/S2352-3018(21)00071-0. Erratum in: Lancet HIV. 2021 Dec;8(12):e734. PMID: 34197772.

The ATEAM Study: Feasibility of an Ingestible Sensor System to Measure PrEP Adherence in YMSM (2015-2020)

  • Ibrahim ME, Brooks KM, Castillo-Mancilla JR, McHugh C, Morrow M, Brothers J, MaWhinney S, Hosek S, Huhn G, Anderson PL. Short Communication: Bioequivalence of Tenofovir and Emtricitabine After Coencapsulation with the Proteus Ingestible Sensor. AIDS Res Hum Retroviruses. 2018 Oct;34(10):835-837. doi: 10.1089/AID.2018.0081. Epub 2018 Sep 5. PMID: 30047286; PMCID: PMC6204565.

  • Brooks KM, Ibrahim ME, Castillo-Mancilla JR, MaWhinney S, Alexander K, Tilden S, Kerr BJ, Ellison L, McHugh C, Bushman LR, Kiser JJ, Hosek S, Huhn GD, Anderson PL. Pharmacokinetics of tenofovir monoester and association with intracellular tenofovir diphosphate following single-dose tenofovir disoproxil fumarate. J Antimicrob Chemother. 2019 Aug 1;74(8):2352-2359. doi: 10.1093/jac/dkz187. PMID: 31093649; PMCID: PMC8420957.

The EPIC Study: Enhancing PrEP in Community Settings

  • Mayer KH, Hosek S, Cohen S, Liu A, Pickett J, Warren M, Krakower D, Grant R. Antiretroviral pre-exposure prophylaxis implementation in the United States: a work in progress. J Int AIDS Soc. 2015 Jul 20;18(4 Suppl 3):19980. doi: 10.7448/IAS.18.4.19980. PMID: 26198345; PMCID: PMC4509893.

  • Koss CA, Hosek SG, Bacchetti P, Anderson PL, Liu AY, Horng H, Benet LZ, Kuncze K, Louie A, Saberi P, Wilson CM, Gandhi M. Comparison of Measures of Adherence to Human Immunodeficiency Virus Preexposure Prophylaxis Among Adolescent and Young Men Who Have Sex With Men in the United States. Clin Infect Dis. 2018 Jan 6;66(2):213-219. doi: 10.1093/cid/cix755. PMID: 29020194; PMCID: PMC5850042.

  • Fuchs JD, Stojanovski K, Vittinghoff E, McMahan VM, Hosek SG, Amico KR, Kouyate A, Gilmore HJ, Buchbinder SP, Lester RT, Grant RM, Liu AY. A Mobile Health Strategy to Support Adherence to Antiretroviral Preexposure Prophylaxis. AIDS Patient Care STDS. 2018 Mar;32(3):104-111. doi: 10.1089/apc.2017.0255. PMID: 29565183; PMCID: PMC5865612.

  • Liu AY, Vittinghoff E, von Felten P, Rivet Amico K, Anderson PL, Lester R, Andrew E, Estes I, Serrano P, Brothers J, Buchbinder S, Hosek S, Fuchs JD. Randomized Controlled Trial of a Mobile Health Intervention to Promote Retention and Adherence to Preexposure Prophylaxis Among Young People at Risk for Human Immunodeficiency Virus: The EPIC Study. Clin Infect Dis. 2019 May 30;68(12):2010-2017. doi: 10.1093/cid/ciy810. PMID: 30239620; PMCID: PMC6541706.

Project PrEPare (ATN 113): An Open Label Demonstration Project and Phase II Safety Study of PrEP Use Among 15 to 17 Year Old YMSM

  • Hosek SG, Landovitz RJ, Kapogiannis B, Siberry GK, Rudy B, Rutledge B, Liu N, Harris DR, Mulligan K, Zimet G, Mayer KH, Anderson P, Kiser JJ, Lally M, Brothers J, Bojan K, Rooney J, Wilson CM. Safety and Feasibility of Antiretroviral Preexposure Prophylaxis for Adolescent Men Who Have Sex With Men Aged 15 to 17 Years in the United States. JAMA Pediatr. 2017 Nov 1;171(11):1063-1071. doi: 10.1001/jamapediatrics.2017.2007. PMID: 28873128; PMCID: PMC5710370.

Project PrEPare (ATN 110): An Open Label Demonstration Project and Phase II Safety Study of PrEP

  • Hosek SG, Rudy B, Landovitz R, Kapogiannis B, Siberry G, Rutledge B, Liu N, Brothers J, Mulligan K, Zimet G, Lally M, Mayer KH, Anderson P, Kiser J, Rooney JF, Wilson CM; Adolescent Trials Network (ATN) for HIVAIDS Interventions. An HIV Preexposure Prophylaxis Demonstration Project and Safety Study for Young MSM. J Acquir Immune Defic Syndr. 2017 Jan 1;74(1):21-29. doi: 10.1097/QAI.0000000000001179. PMID: 27632233; PMCID: PMC5140725.

iPrEx OLE: Emtricitabine/Tenofovir Disoproxil Fumarate for HIV Prevention in Men

  • Grant RM, Anderson PL, McMahan V, Liu A, Amico KR, Mehrotra M, Hosek S, Mosquera C, Casapia M, Montoya O, Buchbinder S, Veloso VG, Mayer K, Chariyalertsak S, Bekker LG, Kallas EG, Schechter M, Guanira J, Bushman L, Burns DN, Rooney JF, Glidden DV; iPrEx study team. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis. 2014 Sep;14(9):820-9. doi: 10.1016/S1473-3099(14)70847-3. Epub 2014 Jul 22. PMID: 25065857; PMCID: PMC6107918.

Project PrEPare (ATN 082): PrEP in YMSM

  • Hosek SG, Siberry G, Bell M, Lally M, Kapogiannis B, Green K, Fernandez MI, Rutledge B, Martinez J, Garofalo R, Wilson CM; Adolescent Trials Network for HIVAIDS Interventions (ATN). The acceptability and feasibility of an HIV preexposure prophylaxis (PrEP) trial with young men who have sex with men. J Acquir Immune Defic Syndr. 2013 Apr 1;62(4):447-56. doi: 10.1097/QAI.0b013e3182801081. PMID: 24135734; PMCID: PMC3656981.

  • Hosek SG, Green KR, Siberry G, Lally M, Balthazar C, Serrano PA, Kapogiannis B; The Adolescent Medicine Trials Network for HIV/AIDS Interventions. Integrating Behavioral HIV Interventions into Biomedical Prevention Trials with Youth: Lessons from Chicago's Project PrEPare. J HIV AIDS Soc Serv. 2013;12(3-4):10.1080/15381501.2013.773575. doi: 10.1080/15381501.2013.773575. PMID: 24223514; PMCID: PMC3818104.

Community HIV & Violence Prevention Interventions

#ChopViolence/#ChopHIV: A Tailored Violence Prevention Intervention for Black Young MSM and Transgender Women from the House Ball Community to Improve HIV Outcomes and Decrease Exposure to Violence (2020-2023)

  • Manuscripts in-press.

POSSE Project: A Community-Level Intervention for Black YMSM

  • Hosek, Sybil et al. “Comparison of Two Distinct House Ball Communities Involved in an HIV Prevention Study: Baseline Data from the POSSE Project.” Journal of HIV/AIDS & social services vol. 18,4 (2019): 399-416. doi:10.1080/15381501.2019.1673868

  • Hotton, Anna L et al. “Socio-structural Factors Associated with Mental Health, Substance Use, and HIV Risk Among Black Sexual and Gender Minorities in the House and Ball Community.” AIDS and behavior vol. 24,8 (2020): 2319-2326. doi:10.1007/s10461-020-02791-8

  • Harper, Gary W et al. “It's a Kiki!: Developmental benefits of the Kiki scene for Black gay/bisexual/transgender adolescents/emerging adults.” Journal of LGBT youth vol. 19,1 (2022): 31-52. doi:10.1080/19361653.2020.1813672

An HIV Intervention Tailored for Black YMSM in the House Ball Community

  • Hosek SG, Lemos D, Hotton AL, Fernandez MI, Telander K, Footer D, Bell M. An HIV intervention tailored for black young men who have sex with men in the House Ball Community. AIDS Care. 2015;27(3):355-62. doi: 10.1080/09540121.2014.963016. Epub 2014 Oct 10. PMID: 25300319; PMCID: PMC4305476.

  • Lemos D, Hosek SG, Bell M. Reconciling Reality with Fantasy: Exploration of the Sociocultural Factors influencing HIV Transmission among Black Young Men who have Sex with Men (BYMSM) within the House Ball Community: A Chicago Study. J Gay Lesbian Soc Serv. 2015;27(1):64-85. doi: 10.1080/10538720.2015.988837. PMID: 26034382; PMCID: PMC4449151.

  • Telander K, Hosek SG, Lemos D, Jeremie-Brink G. 'Ballroom itself can either make you or break you' - Black GBT Youths' psychosocial development in the House Ball Community. Glob Public Health. 2017 Nov;12(11):1391-1403. doi: 10.1080/17441692.2017.1293123. Epub 2017 Mar 3. PMID: 28278745; PMCID: PMC6095463.

Intervention Research for Youth with HIV

AllyQuest: Engaging HIV+ YMSM in Care through Social Networking and Gamification

  • Hightow-Weidman, Lisa et al. “A Gamified Smartphone App to Support Engagement in Care and Medication Adherence for HIV-Positive Young Men Who Have Sex With Men (AllyQuest): Development and Pilot Study.” JMIR public health and surveillance vol. 4,2 e34. 30 Apr. 2018, doi:10.2196/publichealth.8923

A Pilot Adherence Intervention for HIV-Infected Youth

  • Martinez J, Hosek SG. An exploration of the down-low identity: nongay-identified young African-American men who have sex with men. J Natl Med Assoc. 2005 Aug;97(8):1103-12. PMID: 16173325; PMCID: PMC2575973.

  • Martinez J, Hosek SG, Carleton RA. Screening and assessing violence and mental health disorders in a cohort of inner city HIV-positive youth between 1998-2006. AIDS Patient Care STDS. 2009 Jun;23(6):469-75. doi: 10.1089/apc.2008.0178. PMID: 19519231; PMCID: PMC2856564.

Medication Adherence in HIV-Infected Youth

  • Hosek SG, Harper GW, Domanico R. Predictors of medication adherence among HIV-infected youth. Psychol Health Med. 2005 May;10(2):166-179. doi: 10.1080/1354350042000326584. PMID: 25705113; PMCID: PMC4334460.

Epidemiological HIV Cohort & Health Disparities Research

Keeping it LITE-1: Exploring HIV Risk in Vulnerable Youth with Limited Interaction

  • Serrano PA, Daubert E, Munoz A, Hosek SG, French AL. Effect of Truvada lawsuit advertising on preexposure prophylaxis attitudes and decisions among sexual and gender minority youth and young adults at risk for HIV. AIDS. 2021 Jan 1;35(1):131-139. doi: 10.1097/QAD.0000000000002728. PMID: 33031102; PMCID: PMC7718403.

  • Gleason N, Serrano PA, Muñoz A, French A, Hosek S. Limited Interaction Targeted Epidemiology of HIV in Sexual and Gender Minority American Adolescents and Adults: Feasibility of the Keeping it LITE Study. JMIR Form Res. 2021 Nov 26;5(11):e30761. doi: 10.2196/30761. PMID: 34346403; PMCID: PMC8665391.

  • Fitch C, Haberer JE, Serrano PA, Muñoz A, French AL, Hosek SG. Individual and structural-level Correlates of Pre-exposure Prophylaxis (PrEP) lifetime and current use in a nationwide sample of young sexual and gender minorities. AIDS Behav. 2022 Apr 16. doi: 10.1007/s10461-022-03656-y. Epub ahead of print. PMID: 35429311.

  • Gleason N, Serrano PA, Muñoz A, French AL, Hosek SG. Experiences of Online Racialized Sexual Discrimination among Sexual and Gender Minorities in the United States: Online Survey Data from Keeping It LITE. J Sex Res. 2022 Aug 9:1-6. doi: 10.1080/00224499.2022.2103633. Epub ahead of print. PMID: 35943344.

Multicenter AIDS Cohort Study & Women's Interagency HIV Study Cohort Studies

  • French AL, Grennan D, Daubert E, Seaberg EC, Peters M, Augenbraun M, Fischl M, Kassaye S, Franco R, Kuniholm M, Adimora AA, Workowski K, Weber KM. Decreases in markers of monocyte/macrophage activation after hepatitis C eradication in HIV/hepatitis C virus coinfected women. AIDS. 2021 Jul 15;35(9):1433-1438. doi: 10.1097/QAD.0000000000002869. PMID: 33710024; PMCID: PMC8845487.

  • Haley DF, Edmonds A, Ramirez C, French AL, Tien P, Thio CL, Witt MD, Seaberg EC, Plankey MW, Cohen MH, Adimora AA. Direct-Acting Antiviral Hepatitis C Treatment Cascade and Barriers to Treatment Initiation Among US Men and Women With and Without HIV. J Infect Dis. 2021 Jun 15;223(12):2136-2144. doi: 10.1093/infdis/jiaa686. PMID: 33141170; PMCID: PMC8205633.

  • D'Souza G, Springer G, Gustafson D, Kassaye S, Alcaide ML, Ramirez C, Sharma A, Palella FJ, Tien PC, Detels R, Kempf MC, Lahiri CD, Rinaldo CR, French AL, Margolick JB, Adimora AA. COVID-19 symptoms and SARS-CoV-2 infection among people living with HIV in the US: the MACS/WIHS combined cohort study. HIV Res Clin Pract. 2020 Oct;21(5):130-139. doi: 10.1080/25787489.2020.1844521. Epub 2020 Nov 19. PMID: 33211636; PMCID: PMC7682380.

  • D'Souza G, Tong W, Gustafson D, Alcaide ML, Lahiri CD, Sharma A, French AL, Palella FJ, Kempf MC, Mimiaga MJ, Ramirez C, Kassaye S, Rinaldo CR, Brown TT, Tien PC, Adimora AA. SARS-CoV-2 Infection Among People Living With HIV Compared With People Without HIV: Survey Results From the MACS-WIHS Combined Cohort Study. J Acquir Immune Defic Syndr. 2022 Jan 1;89(1):1-8. doi: 10.1097/QAI.0000000000002822. PMID: 34878431; PMCID: PMC8667184.

  • Aaron KJ, Brill I, Causey-Pruitt Z, Murphy K, Augenbraun M, Kassaye S, Milam JE, Seidman D, French AL, Gange SJ, Adimora AA, Sheth AN, Fischl MA, Van Der Pol B, Marrazzo J, Kempf MC, Dionne-Odom J. Factors associated with syphilis seroprevalence in women with and at-risk for HIV infection in the Women's Interagency HIV Study (1994-2015). Sex Transm Infect. 2022 Feb;98(1):4-10. doi: 10.1136/sextrans-2020-054674. Epub 2021 Jan 6. PMID: 33408096.

  • Daubert E, French AL, Burgess HJ, Sharma A, Gustafson D, Cribbs SK, Weiss DJ, Ramirez C, Konkle-Parker D, Kassaye S, Weber KM. Association of Poor Sleep With Depressive and Anxiety Symptoms by HIV Disease Status: Women's Interagency HIV Study. J Acquir Immune Defic Syndr. 2022 Feb 1;89(2):222-230. doi: 10.1097/QAI.0000000000002847. PMID: 34732681; PMCID: PMC8740603.